Products & Services

iCell® Cardiomyocytes

Proven, Predictive, Published

Description
Performance Data
Product Highlights
Protocols
Publications
Description

Heart disease encompasses a wide range of conditions that can be a result of genetics, physiologic, and metabolic disorders as well as adverse drug reactions. The availability of human cell models that could be used to interrogate these various factors would have a profound impact on the effort to find new medicines and cures for heart disease. Derived from induced pluripotent stem cells (iPSCs), iCell® Cardiomyocytes from FUJIFILM Cellular Dynamics, Inc. (FCDI), enable a wide range of applications spanning disease research, drug discovery, safety and toxicity testing, and regenerative medicine.



  • Industry Standard With the most peer-reviewed publications and supported application protocols, iCell Cardiomyocytes are the in vitro model of choice.
  • Reproducible Research High purity and rigorous quality control ensure the same performance and reproducible results with every batch of iCell Cardiomyocytes.
  • Human Relevance iCell Cardiomyocytes recapitulate healthy human cardiac biology and function and express relevant targets and pathways for heart disease research.
  • Diverse Availability iCell Cardiomyocytes are now available from two backgrounds with no known disease-related genotypes: donors 01434 and 11713. Also available are cardiomyocytes generated from diseased backgrounds and engineered genotypes, including MyCell® Cardiomyocytes (R403Q), a model of hypertrophic cardiomyopathy derived from donor 01178 with genotype MYH7 R403Q.


  iCell Cardiomyocytes, 01434 iCell Cardiomyocytes, 11713
Sex Female Female
Age Group (at collection) <18 35 - 39
Ethnicity Caucasian Caucasian
Tissue Source Fibroblast PBMC
Reprogramming Method Retroviral Transduction Episomal
Performance Data

Figure 1: iCell Cardiomyocytes are a High-Purity Cardiac Population.
Flow cytometry analysis and immunostaining show that iCell Cardiomyocytes are typically >95% cTNT+) with intact sarcomeric myofilament organization. (Data were adapted from Kattman et al., 2011.)

Figure 2: iCell Cardiomyocytes Recapitulate Native Cardiac Function
iCell Cardiomyocytes form a spontaneously beating monolayer within 7 days. iCell Cardiomyocytes contain the expected human cardiac ionic currents and show the expected effects when exposed to compounds including ion channel blockers. (Data were adapted from Ma et al., 2011).

   

Figure 3: iCell Cardiomyocytes have Appropriate Sarcomeric Organization, Calcium Handling and Intact Excitation-Contraction Coupling.
Their electrophysiological activity can be pharmacologically modulated and quantified by recording the electrical activity using a multielectrode array (MEA). The field potential duration (FPD) increases or decreases as expected when exposed to ion channel-blocking drugs for key cardiac channels.

Figure 4: Intracellular Calcium (Ca2+) Handling Provides a High-throughput Biomarker for Ion Channel and GPCR Activity.
Electrical activity at the membrane is controlled by ion channels and GPCRs. This activity drives intracellular Ca2+ handling. Panel A shows representative calcium handling waveforms at baseline. Panels B and C show the effect of the GPCR β-adrenergic agonist ISO or the IKr channel blocker E-4031, respectively.

   
Product Highlights
Protocols

Protocols

Application protocols for iCell Cardiomyocytes have been optimized for cells derived from the genetic background 01434. A subset of these protocols have been tested with cells derived from the genetic background 11713 and require no modification. Additional applications have not yet been tested using 11713. Protocols supported for both iCell Cardiomyocytes, 01434 and 11713:



Full List of Application Protocols



User Documentation

Publications

Lagrutta A, Zeng H, Imredy J, Balasubramanian B, Dech S, Lis E, Wang J, Zhai J, DeGeorge J, Sannajust F. (2016) Interaction between AMIO and Hepatitis-C Virus Nucleotide Inhibitors in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes and HEK-293 Cav1.2 Over-expressing Cells. Toxicol Appl Pharmacol 308:66-76.


Necela B, Axenfeld B, Serie D, Kachergus J, Perez E, Thompson E, Norton N. (2017) The Antineoplastic Drug, TRAST, Dysregulates Metabolism in iPSC-derived Cardiomyocytes. Clin Transl Med 6(1):5.


Huo J, Kamalakar A, Yang X, Word B, Stockbridge N, Lyn-Cook B, Pang L. (2017) Evaluation of Batch Variations in Induced Pluripotent Stem Cell-derived Human Cardiomyocytes from 2 Major Suppliers. Toxicol Sci 156(1):25-38.


Zeng H, Balasubramanian B, Lagrutta A, Sannajust. (2018) Response of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes to Several Pharmacological Agents When Intrinsic Syncytial Pacing Is Overcome by Acute External Stimulation. J Pharmacol Toxicol Methods (91):18-26.


Schocken D, Stohlman J, Vicente J, Chan D, Patel D, Matta MK, Patel V, Brock M, Millard D, Ross J, Strauss DG, Blinova K. (2018) Comparative Analysis of Media Effects on Human Induced Pluripotent Stem Cell-derived Cardiomyocytes in Proarrhythmia Risk Assessment. J Pharmacol Toxicol Methods (90):39-47.


Bedut S, Seminatore-Nole C, Lamamy V, Caignard S, Boutin JA, Nosjean O, Stephan JP, Coge F. (2016) High-throughput Drug Profiling with Voltage- and Calcium-sensitive Fluorescent Probes in Human iPSC-derived Cardiomyocytes. Am J Physiol Heart Circ Physiol 311(1):H44-53.


Additional Publications


  • Ordering InformationFor best pricing please log in or register
    Catalog # Description Quantity Price
    R1057 iCell Cardiomyocytes Kit, 01434

    Each kit contains:

    • Cryopreserved iCell Cardiomyocytes
    • 30 ml iCell Cardiomyocytes Plating Medium
    • 100 ml iCell Cardiomyocytes Maintenance Medium
    • User’s Guide
    ≥1 x 106
    Viable Cells/Vial
    $595
    Inquire About Pricing & Availability
    CMC-100-010-000.5 iCell Cardiomyocytes Kit, 01434

    Each kit contains:

    • Cryopreserved iCell Cardiomyocytes
    • 30 ml iCell Cardiomyocytes Plating Medium
    • 100 ml iCell Cardiomyocytes Maintenance Medium
    • User’s Guide
    ≥2 x 106
    Viable Cells/Vial
    $830
    Inquire About Pricing & Availability
    R1132 iCell Cardiomyocytes Kit 3 Pack, 01434

    Each kit contains:

    • 3 Vials Cryopreserved iCell Cardiomyocytes
    • 30 ml Plating Medium
    • 2 x 100 ml Maintenance Medium
    • User’s Guide
    3 Vials at
    ≥1 x 106
    Viable Cells/Vial
    $1500
    Inquire About Pricing & Availability
    R1007 iCell Cardiomyocytes Kit, 01434

    Each kit contains:

    • Cryopreserved iCell Cardiomyocytes
    • 30 ml Plating Medium
    • 2 x 100 ml Maintenance Medium
    • User’s Guide
    ≥4 x 106
    Viable Cells/Vial
    $1500
    Inquire About Pricing & Availability
    R1105 iCell Cardiomyocytes Kit, 11713

    Each kit contains:

    • Cryopreserved iCell Cardiomyocytes
    • 30 ml Plating Medium
    • 100 ml Maintenance Medium
    • User’s Guide
    ≥1 x 106
    Viable Cells/Vial
    $595
    Inquire About Pricing & Availability
    R1117 iCell Cardiomyocytes Kit 3 Pack, 11713

    Each kit contains:

    • 3 Vials Cryopreserved iCell Cardiomyocytes
    • 30 ml Plating Medium
    • 2 x 100 ml Maintenance Medium
    • User’s Guide
    3 Vials at
    ≥1 x 106
    Viable Cells/Vial
    $1500
    Inquire About Pricing & Availability
    R1106 iCell Cardiomyocytes Kit, 11713

    Each kit contains:

    • Cryopreserved iCell Cardiomyocytes
    • 30 ml Plating Medium
    • 2 x 100 ml Maintenance Medium
    • User’s Guide
    ≥4 x 106
    Viable Cells/Vial
    $1500
    Inquire About Pricing & Availability
    M1004 iCell Cardiomyocytes Maintenance Medium

    Serum-based medium with pH indicator

    500 ml (5X) $350
    Inquire About Pricing & Availability
    M1003 iCell Cardiomyocytes Maintenance Medium

    Serum-based medium with pH indicator

    100 ml (1X) $125
    Inquire About Pricing & Availability